However, a longer residence time in the circulating blood (slow clearance) and a longer time for tumor uptake and visualization of PD-L1-positive tumors (e.g., tumor visualization at 4 h post-injection with maximum uptake at 24 h [20]) are expected for the 99mTc-anti-PD-L1 radiopharmaceuticals (complete antibodies) [20] compared to the 99mTc-peptides examined in this study (tumor visualization at 1 h post-injection). The gene discussed is CD274; the disease is neoplasm.